print_label | resize_label

FASLODEX (fulvestrant) indication

FASLODEX indication

FASLODEX 500 mg or FASLODEX 250 mg (depending on the country)* is indicated for the treatment of postmenopausal women with oestrogen receptor-positive locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy or disease progression on therapy with an anti-oestrogen.1

Following the recent approval of FASLODEX 500 mg in European Union (EU) countries, FASLODEX 500 mg is now the recommended dose in the EU and USA, and FASLODEX 250 mg in countries throughout the rest of the world. Regulatory submissions for the 500 mg dose are ongoing.

*The licensed indication may vary in different countries. Please refer to your local Prescribing Information and take this into consideration before prescribing this product.